» Articles » PMID: 37122392

Anti-PLAR Antibody Development During NELL1-Associated Membranous Glomerulonephritis Treatment: A Case Report

Overview
Journal Kidney Med
Specialty Nephrology
Date 2023 May 1
PMID 37122392
Authors
Affiliations
Soon will be listed here.
Abstract

A Japanese man in his early 70s was referred to our hospital because of massive proteinuria. Analysis of his kidney biopsy demonstrated glomerular subepithelial immune deposits containing immunoglobulin (Ig)G, which was dominant for the IgG1 subclass. Immunoperoxidase staining for neural epidermal growth factor-like 1 protein (NELL1) was positive on the glomerular capillary walls, whereas neither serum anti-phospholipase A2 receptor (PLAR) antibodies nor immunofluorescence staining for PLAR was positive. Detailed investigation revealed no associated conditions, including underlying malignancies, and thus he was diagnosed as having NELL1-associated idiopathic membranous nephropathy (MN). The patient was treated with steroids, which substantially improved his nephrotic syndrome. Interestingly, serum anti-NELL1 as well as anti-PLAR antibodies became positive during his clinical course. Serology-based approaches are currently proposed for the treatment of patients suspected of having MN; however, an accurate diagnosis of the present patient would have been difficult if such an approach was performed only at a later phase of the disease. Several target antigens for the glomerular immune deposits observed in patients with MN have recently been identified, and dual positivity of antibodies to these antigens reportedly occurs in some patients. Further accumulation and analyses of such patients are needed to establish more appropriate diagnostic approaches for MN.

Citing Articles

The Prevalence, Characteristics, and Putative Mechanisms of Dual Antigen-Positive Membranous Nephropathy: The Underestimated Condition.

Uchida T, Oda T Int J Mol Sci. 2024; 25(11).

PMID: 38892120 PMC: 11172907. DOI: 10.3390/ijms25115931.


NELL1 membranous nephropathy: clinical associations provide mechanistic clues.

Andeen N, Kung V, Avasare R Front Nephrol. 2024; 4:1323432.

PMID: 38596642 PMC: 11002321. DOI: 10.3389/fneph.2024.1323432.


Clinicopathological and prognostic characteristics of idiopathic membranous nephropathy with dual antigen positivity.

Yang L, Wang G, Ye N, Xu X, Cheng W, Sun L Front Immunol. 2024; 14:1297107.

PMID: 38250076 PMC: 10796489. DOI: 10.3389/fimmu.2023.1297107.

References
1.
De Vriese A, Glassock R, Nath K, Sethi S, Fervenza F . A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol. 2016; 28(2):421-430. PMC: 5280030. DOI: 10.1681/ASN.2016070776. View

2.
Stehle T, Audard V, Ronco P, Debiec H . Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant. 2015; 30(6):1047-50. DOI: 10.1093/ndt/gfv080. View

3.
Grace Choung H, Goldman B . Segmental membranous nephropathy. Clin Exp Nephrol. 2021; 25(7):700-707. DOI: 10.1007/s10157-021-02056-1. View

4.
Wang G, Sun L, Dong H, Wang Y, Xu X, Zhao Z . Neural Epidermal Growth Factor-Like 1 Protein-Positive Membranous Nephropathy in Chinese Patients. Clin J Am Soc Nephrol. 2021; 16(5):727-735. PMC: 8259482. DOI: 10.2215/CJN.11860720. View

5.
Larsen C, Messias N, Silva F, Messias E, Walker P . Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2012; 26(5):709-15. DOI: 10.1038/modpathol.2012.207. View